Faculty, Staff and Student Publications

Language

English

Publication Date

12-1-2025

Journal

Future Oncology

DOI

10.1080/14796694.2025.2579882

PMID

41230651

PMCID

PMC12698039

PubMedCentral® Posted Date

11-13-2025

PubMedCentral® Full Text Version

Post-print

Abstract

The BREAKWATER Phase III study investigated encorafenib and cetuximab plus mFOLFOX6 versus chemotherapy with or without bevacizumab for the treatment of patients with previously untreated BRAF V600E – mutant metastatic colorectal cancer. The study showed significantly improved objective response rate by blinded independent central review, and significantly longer progression-free survival by blinded independent central review and overall survival in patients treated with first-line encorafenib and cetuximab plus mFOLFOX6 compared with chemotherapy with or without bevacizumab. The safety profiles were consistent with those known for each agent. These results led to the approval of encorafenib and cetuximab plus mFOLFOX6 for the treatment of BRAF V600E-mutant metastatic colorectal cancer, including in the first line. This paradigm shift in metastatic colorectal cancer highlights the importance for early genomic testing to identify patients who would benefit from this new treatment option. We discuss the results from BREAKWATER – including progression-free survival by blinded independent central review, overall survival, objective response rate by blinded independent central review in all participants, and safety – and the meaning of these results for clinical practice as a new treatment option and the need for earlier genomic testing.

Keywords

Humans, Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Sulfonamides, Cetuximab, Mutation, Carbamates, Fluorouracil, Organoplatinum Compounds, Clinical Trials, Phase III as Topic, Middle Aged, Male, Neoplasm Metastasis, Progression-Free Survival, Female, Aged, Treatment Outcome, Metastatic colorectal cancer, BRAF-mutant, Encorafenib, First-line

Comments

Clinical Trial Registration: www.clinicaltrials.gov identifier is NCT04607421.

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.